Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
about
P2860
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Gemcitabine combined with the ...... r, randomized phase IIb study.
@en
Gemcitabine combined with the ...... r, randomized phase IIb study.
@nl
type
label
Gemcitabine combined with the ...... r, randomized phase IIb study.
@en
Gemcitabine combined with the ...... r, randomized phase IIb study.
@nl
prefLabel
Gemcitabine combined with the ...... r, randomized phase IIb study.
@en
Gemcitabine combined with the ...... r, randomized phase IIb study.
@nl
P2093
P2860
P356
P1433
P1476
Gemcitabine combined with the ...... r, randomized phase IIb study.
@en
P2093
A Kerkhoff
B Schultheis
D M Behringer
D Strumberg
F Overkamp
F Schlegel
P2860
P304
P356
10.1093/ANNONC/MDX343
P577
2017-10-01T00:00:00Z